223 related articles for article (PubMed ID: 17062712)
1. New potential targets for treating myeloma bone disease.
Roodman GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
[TBL] [Abstract][Full Text] [Related]
2. Treatment strategies for bone disease.
Roodman GD
Bone Marrow Transplant; 2007 Dec; 40(12):1139-46. PubMed ID: 17680018
[TBL] [Abstract][Full Text] [Related]
3. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
4. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O
Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218
[TBL] [Abstract][Full Text] [Related]
5. [Bone disease in multiple myeloma and its mechanism].
Abe M
Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
[TBL] [Abstract][Full Text] [Related]
6. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis and management of myeloma bone disease.
Christoulas D; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
[TBL] [Abstract][Full Text] [Related]
8. Bone markers in multiple myeloma.
Heider U; Fleissner C; Zavrski I; Kaiser M; Hecht M; Jakob C; Sezer O
Eur J Cancer; 2006 Jul; 42(11):1544-53. PubMed ID: 16765040
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic approaches to myeloma bone disease: an evolving story.
Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology of multiple myeloma bone disease.
Lentzsch S; Ehrlich LA; Roodman GD
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of myeloma bone disease.
Roodman GD
J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
[TBL] [Abstract][Full Text] [Related]
12. [Mechanisms for formation of myeloma bone disease].
Yata K; Abe M; Matsumoto T
Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
[TBL] [Abstract][Full Text] [Related]
13. Myeloma bone disease and treatment options.
Yeh HS; Berenson JR
Eur J Cancer; 2006 Jul; 42(11):1554-63. PubMed ID: 16797971
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of myeloma bone disease.
Roodman GD
Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
[TBL] [Abstract][Full Text] [Related]
15. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.
Giuliani N; Mangoni M; Rizzoli V
Exp Hematol; 2009 Aug; 37(8):879-86. PubMed ID: 19446662
[TBL] [Abstract][Full Text] [Related]
16. Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells.
Silvestris F; Cafforio P; De Matteo M; Calvani N; Frassanito MA; Dammacco F
Clin Cancer Res; 2008 Oct; 14(19):6081-91. PubMed ID: 18829486
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
18. An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors.
Zannettino AC; Farrugia AN; To LB; Atkins GJ
Methods Mol Med; 2005; 113():245-56. PubMed ID: 15968108
[TBL] [Abstract][Full Text] [Related]
19. Bone destruction in multiple myeloma.
Matsumoto T; Abe M
Ann N Y Acad Sci; 2006 Apr; 1068():319-26. PubMed ID: 16831932
[TBL] [Abstract][Full Text] [Related]
20. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]